MicroRNA Momentum Builds, But Will Big Pharma Embrace It?
While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.
You may also be interested in...
In the latest of a handful of big pharma RNA partnerships, Bristol-Myers and Santaris have entered into a broad discovery and development deal. For the biotech, it brings a new partner into the string of deals that continue to be its main source of capital.
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
Starting with a $45 million upfront, the potential value of this deal, which centers on three pre-clinical cardiovascular targets, could reach up to $1 billion, if the companies meet regulatory and commercial milestones.